Vertex Pharmaceuticals Files 8-K on Financials and Personnel
Ticker: VRTX · Form: 8-K · Filed: Aug 4, 2025 · CIK: 875320
Sentiment: neutral
Topics: financial-reporting, corporate-governance, sec-filing
Related Tickers: VRTX
TL;DR
Vertex Pharma dropped an 8-K: financials, board changes, and more. Check it out.
AI Summary
Vertex Pharmaceuticals Incorporated filed an 8-K on August 4, 2025, reporting on results of operations, financial condition, and changes in its board and officer composition. The filing also includes financial statements and exhibits, with the company's principal executive offices located at 50 Northern Avenue, Boston, MA.
Why It Matters
This 8-K filing provides investors with crucial updates on Vertex Pharmaceuticals' financial performance and any significant changes in its leadership or board structure, impacting investor confidence and strategic outlook.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on standard corporate events and financial information, not indicating any immediate or unusual risks.
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- Massachusetts (location) — State of incorporation
- 000-19319 (other) — SEC File Number
- 04-3039129 (other) — I.R.S. Employer Identification No.
- 50 Northern Avenue, Boston, Massachusetts 02210 (location) — Address of principal executive offices
- 617-341-6100 (phone_number) — Registrant's telephone number
- August 4, 2025 (date) — Date of Report
FAQ
What specific items are covered under 'Results of Operations and Financial Condition' in this 8-K?
The filing indicates that 'Results of Operations and Financial Condition' are reported, but the specific details of these results are not provided in the provided text snippet.
What changes are reported regarding directors or officers?
The filing states that it covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', but the specific individuals or changes are not detailed in the provided text.
What is the filing date and the earliest event date reported?
The filing date and the date of the earliest event reported are both August 4, 2025.
Where are Vertex Pharmaceuticals' principal executive offices located?
Vertex Pharmaceuticals' principal executive offices are located at 50 Northern Avenue, Boston, Massachusetts 02210.
What is the SIC code for Vertex Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Vertex Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding VERTEX PHARMACEUTICALS INC / MA (VRTX).